The purpose of the study is to evaluate the efficacy and safety of the drug in participants whose disease has progressed after at least one prior line of systemic therapy. Participants will receive the medication in a series of treatment visits over several months, with regular check‑ups to see how the cancer is responding and to monitor any side effects. The study will continue until a predetermined follow‑up period is completed.

The study uses a medication called zanidatamab (also known as JZP598), which is given through an intravenous infusion. This medicine is a powder that is first made into a concentrated solution before being given to patients. The maximum daily dose that can be given is 2400 milligrams, and treatment may continue for up to three years.

The main goal of this research is to determine how well zanidatamab works in treating these different types of cancer. The study will look at whether tumors respond to the treatment by shrinking or disappearing. Doctors will monitor patients regularly using scans to check how the tumors are responding to the treatment and to watch for any side effects that may occur.

The purpose of the study is to learn more about how well the treatment works and how safe it is for participants. The study will involve taking the medication by mouth for a period of up to 36 months. Participants will be monitored regularly to see how their tumors respond to the treatment and to check for any side effects. The study will also look at how long the treatment keeps the disease under control and how it affects the overall health and quality of life of the participants.

Participants in the study will have regular check-ups and tests to track their progress. These tests will help researchers understand the effectiveness of the treatment and any potential risks. The study aims to provide valuable information that could lead to better treatment options for people with these types of tumors in the future.

Participants in the study will receive one of several treatments, which may include medications such as Futibatinib, IMFINZI (also known as DURVALUMAB or MEDI4736), Lynparza (containing OLAPARIB), Mekinist (containing TRAMETINIB), IBRANCE (containing PALBOCICLIB), Daurismo (containing GLASDEGIB), Tabrecta (containing CAPMATINIB), Tafinlar (containing DABRAFENIB), Tasigna (containing NILOTINIB), Tyverb (containing LAPATINIB), and Zykadia (containing CERITINIB). Some participants may receive a placebo, which is a substance with no active medication, to compare the effects of the actual treatments.

The purpose of the study is to determine how feasible it is to use NGS to provide a detailed genetic report that can help doctors make informed treatment decisions. The study will monitor participants over a period to see how well they respond to the treatments and to assess their overall survival and progression-free survival, which refers to the time during and after treatment that a patient lives with the disease without it getting worse. The trial will also evaluate the cost-effectiveness of using NGS in treatment planning. Participants will be followed up to see how their tumors respond to the treatments and to gather data on their quality of life during the study period.

The purpose of the study is to determine if this new treatment is safe and feasible for children, adolescents, and young adults with advanced sarcoma. Participants in the study will receive increasing doses of the to see how their bodies respond. The study will also look at how effective the treatment is in reducing the size of the tumors. During the trial, participants will be closely monitored for any side effects and to see how long the treatment stays in their bodies.

The study will take place over several years, and participants will receive regular check-ups to monitor their health and the progress of the treatment. The trial aims to provide valuable information on the potential benefits and risks of using in treating advanced sarcoma, which could lead to new treatment options for patients in the future.

The purpose of this study is to evaluate the safety of this new treatment approach in children, adolescents, and young adults who have sarcomas that have not responded well to standard treatments. Participants will receive the NK cell treatment after undergoing a process called lymphoablative chemotherapy and/or low-dose radiotherapy. Lymphoablative chemotherapy is a type of treatment that reduces the number of certain immune cells to make room for the new NK cells to work more effectively. The study will monitor participants for any side effects and assess how well the treatment works over time.

Throughout the study, researchers will also look at various factors, such as the occurrence of infections, the recovery of blood cells, and the overall progression of the disease over a five-year period. They will use imaging techniques to track changes in the tumors and analyze samples to understand how the NK cells interact with the cancer. This research aims to provide new insights into the potential benefits of using NK cells in treating sarcomas, especially for those who have limited options with existing therapies.

The study combines two types of treatment: a medication called trabectedin (given through an intravenous infusion) and low-dose radiation therapy. Trabectedin is administered as a solution that is prepared from a powder and given through a special tube placed in a vein. The dose used in this study is 1.5 milligrams per square meter of body surface.

The main goal of this research is to determine how well tumors respond to this combination treatment, particularly in areas that receive radiation therapy. Throughout the study, researchers will monitor changes in tumor size, track how long the treatment remains effective, and assess its effects on pain levels and overall well-being. They will also carefully watch for any side effects that may occur during treatment.

The purpose of this study is to see how well these medications work together in stopping the progression of these sarcomas over a period of six months. Participants in the study will receive pembrolizumab as an infusion, which means it is given directly into the bloodstream through a vein, and cabozantinib as a tablet taken by mouth. The study will last for up to 24 months, during which time the participants will be monitored regularly to assess the effects of the treatment on their cancer.

Throughout the study, doctors will use imaging techniques like MRI or CT scans to check the size of the tumors and see if they are responding to the treatment. The study aims to determine if the combination of pembrolizumab and cabozantinib can help control the disease and improve the quality of life for patients with these advanced sarcomas. Participants will also be monitored for any side effects from the medications to ensure their safety during the trial.

The purpose of this study is to evaluate how effective these treatments are in managing the disease. Patients participating in the study will be randomly assigned to one of the two treatment groups. The study will last for a period of up to 24 months, during which patients will receive their assigned treatment and be monitored regularly. The main focus is to see how long patients can live without their cancer getting worse, which is known as progression-free survival. Other aspects being studied include the overall response to the treatment, the duration of the response, and the overall survival of the patients.

Throughout the study, patients’ quality of life will also be assessed using a questionnaire designed to understand how the treatment affects their daily living. Additionally, researchers will conduct further studies to identify potential markers that could predict how well patients respond to the treatment and to explore new targets for future therapies. This research aims to improve understanding and treatment of these rare sarcomas, providing valuable insights for future medical advancements.

The treatment involves receiving atezolizumab through an intravenous infusion. Patients will receive up to 1200 mg of the medication per day, with treatment lasting up to 12 months. Some patients will receive only radiotherapy, while others will receive both radiotherapy and atezolizumab. After the treatment period, all patients will undergo surgery to remove the tumor.

The study will look at how much of the tumor is destroyed by examining the tissue removed during surgery. Doctors will also monitor how the immune system responds to the treatment by studying various types of immune cells in the tumor tissue. Throughout the study, patients will have regular check-ups to monitor their health and any side effects from the treatment.